{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:13:40Z","timestamp":1794255220969,"version":"4.9.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010003","name":"Robert W Woodruff Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtct.2025.05.028","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:52:10Z","timestamp":1749610330000},"page":"610-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-6399","authenticated-orcid":false,"given":"Michelle L.","family":"Schoettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho","family":"Bo-Kyoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-9203","authenticated-orcid":false,"given":"Christopher E.","family":"Dandoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-3996","authenticated-orcid":false,"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1791-7718","authenticated-orcid":false,"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"Isabella","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-0714","authenticated-orcid":false,"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-3245","authenticated-orcid":false,"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2025.05.028_bib0001","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2025.05.028_bib0002","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.028_bib0003","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.028_bib0004","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.27186","article-title":"D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study","volume":"99","author":"Schoettler","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.028_bib0005","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.028_bib0006","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr"},{"issue":"8","key":"10.1016\/j.jtct.2025.05.028_bib0007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.028_bib0008","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.028_bib0009","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and complement activation as predictors of survival in adult allogeneic hematopoietic","volume":"5","author":"Gavriilaki","year":"2021","journal-title":"Cell Transplantation. Hemasphere"},{"key":"10.1016\/j.jtct.2025.05.028_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2023.03.001","article-title":"Pathway-driven rare germline variants associated with transplant-associated thrombotic microangiopathy (TA-TMA)","volume":"225","author":"Zhang","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtct.2025.05.028_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619892684","article-title":"Von Willebrand factor as a predictor for transplant-associated thrombotic microangiopathy","volume":"26","author":"Xu","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"10.1016\/j.jtct.2025.05.028_bib0012","doi-asserted-by":"crossref","first-page":"392.e1","DOI":"10.1016\/j.jtct.2022.04.019","article-title":"Transplantation-associated thrombotic microangiopathy risk stratification: is there a window of opportunity to improve outcomes?","volume":"28","author":"Jodele","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.028_bib0013","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/bloodadvances.2021004933","article-title":"Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults","volume":"6","author":"Vasu","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.028_bib0014","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/bloodadvances.2023011078","article-title":"Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy","volume":"8","author":"Schoettler","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.028_bib0015","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/bloodadvances.2019001315","article-title":"New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT","volume":"4","author":"Elfeky","year":"2020","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.028_bib0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.028_bib0017","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation\u2013associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2025.05.028_bib0018","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.028_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.028_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41409-022-01852-x","article-title":"Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study","volume":"58","author":"Svec","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.028_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.761726","article-title":"Use of eculizumab in pediatric patients with transplant associated thrombotic microangiopathy","volume":"9","author":"Gomez-Ganda","year":"2021","journal-title":"Front Pediatr"},{"issue":"12","key":"10.1016\/j.jtct.2025.05.028_bib0022","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.028_bib0023","doi-asserted-by":"crossref","first-page":"601.e1","DOI":"10.1016\/j.jtct.2024.03.019","volume":"30","author":"Ben\u00edtez Carabante","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.028_bib0024","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41409-018-0256-8","article-title":"Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy","volume":"54","author":"Mart\u00ednez-Mu\u00f1oz","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.028_bib0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the paediatric diseases and inborn errors working parties of the European society of blood and marrow transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.028_bib0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00277-022-05069-2","article-title":"Comparison of multiple treatments in the management of transplant-related thrombotic microangiopathy: a network meta-analysis","volume":"102","author":"Yang","year":"2023","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.028_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hemonc.2021.09.002","article-title":"Efficacy and safety of recombinant thrombomodulin for the prophylaxis of veno-occlusive complication in allogeneiccit hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"16","author":"Kashyap","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.028_bib0028","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.028_bib0029","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2017.119","article-title":"Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD","volume":"52","author":"Zeisbrich","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.05.028_bib0030","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.028_bib0031","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.028_bib0032","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.028_bib0033","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.028_bib0034","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.028_bib0035","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1111\/trf.15534","article-title":"Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus","volume":"59","author":"Jan","year":"2019","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.028_bib0036","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1705454","article-title":"Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease","volume":"38","author":"Wolff","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.028_bib0037","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.028_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin Transplant"},{"issue":"20","key":"10.1016\/j.jtct.2025.05.028_bib0039","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/bloodadvances.2018020321","article-title":"Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD","volume":"2","author":"Wall","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.05.028_bib0040","article-title":"A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy","volume":"13","author":"Schoettler","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.05.028_bib0041","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.19506","article-title":"Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-A secondary CIBMTR analysis","volume":"205","author":"Schoettler","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.028_bib0042","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/sj.bmt.1704513","article-title":"Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes","volume":"33","author":"George","year":"2004","journal-title":"Bone Marrow Transplantation"},{"issue":"13","key":"10.1016\/j.jtct.2025.05.028_bib0043","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2020002007","article-title":"Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT","volume":"4","author":"Matsui","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.05.028_bib0044","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.jtct.2024.06.021","article-title":"Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the center for international blood and marrow transplant research registry","volume":"30","author":"Cusatis","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.028_bib0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/SHK.0000000000001504","article-title":"Complement activation in human sepsis is related to sepsis-induced disseminated intravascular coagulation","volume":"54","author":"Abe","year":"2020","journal-title":"Shock"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.028_bib0046","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2020.12.010","article-title":"Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-host disease: a nested case-control Study","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.05.028_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.695037","article-title":"Early elevation of complement factor ba is a predictive biomarker for transplant-associated thrombotic microangiopathy","volume":"12","author":"Okamura","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.028_bib0048","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.jtct.2025.05.028_bib0049","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.05.028_bib0050","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation","volume":"24","author":"Horv\u00e1th","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.028_bib0051","article-title":"Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic microangiopathy after stem cell transplantation","volume":"7","author":"Mez\u00f6","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.jtct.2025.05.028_bib0052","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.028_bib0053","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjh.18377","article-title":"Upregulation of HIF-1\u03b1 contributes to complement activation in transplantation-associated thrombotic microangiopathy","volume":"199","author":"Qi","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.05.028_bib0054","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.05.028_bib0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.028_bib0056","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.05.028_bib0057","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.939890","article-title":"Survival analysis of transplant-associated thrombotic microangiopathy under different diagnostic criteria and the efficacy of plasma exchange","volume":"28","author":"Xu","year":"2023","journal-title":"Ann Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.05.028_bib0058","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.jtct.2025.01.205","article-title":"Eculizumab response in pediatric transplant- associated thrombotic microangiopathy- a real- world, multi-institutional experience","volume":"31","author":"Schoettler","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"issue":"3","key":"10.1016\/j.jtct.2025.05.028_bib0059","doi-asserted-by":"crossref","first-page":"336.e1","DOI":"10.1016\/j.jtct.2023.12.017","article-title":"Compassionate use narsoplimab for severe refractory transplantation-associated thrombotic microangiopathy in children","volume":"30","author":"Schoettler","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:20:03Z","timestamp":1762892403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666636725012266"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.028","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}